Sick sinus syndrome: strategies for reducing mortality.
The evolution of sick sinus syndrome is slow, and its clinical and electrocardiographic manifestations are intermittent. A-V and I-V conduction disturbances often arise, but incidence of defects with clinical consequences is too low. Death rate, when large groups are considered, is slightly higher than that of the general population of the same age and with similar pathologies. Mortality depends on concomitant pathologies, on the development of congestive heart failure, on the arterial thromboembolism and on the type of sinus disease. The use of ventricular pacemakers (VVI) did not reduce mortality. Atrial pacing (AAI) gives the auricles electrical stability preventing fibrillation and systemic embolism. The hemodynamic role of the auricles is also preserved. As a consequence, death rate is reduced when AAI is used. In cases with a-v conduction disturbances or with paroxysmal atrial fibrillation, dual chamber pacing (DDD) is preferable because it permits ventricular pacing to be continued even if a-v block or paroxysmal or chronic atrial fibrillation appears. When using ventricular pacing and in cases in which pacing is not considered, warfarin or aspirin can prevent strokes and systemic embolism. In bradycardia-tachycardia syndrome requiring treatment of arrhythmias dual chamber pacemaker must be implanted.
Cosín
J
J
Centro de investigación, Hospital La Fe, Valencia, Spain.
Hernandiz
A
A
Solaz
J
J
Andres
F
F
Olagüe
J
J
D001241:Aspirin / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D010138:Pacemaker, Artificial; D012307:Risk Factors; D012804:Sick Sinus Syndrome / Q000401:mortality* / Q000628:therapy; D014859:Warfarin / Q000008:administration & dosage*
D014859:Warfarin; D001241:Aspirin